On September 13, 2024 Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, reported that it will present a poster with updated results from the RINGSIDE Phase 2 clinical trial of AL102 for the treatment of desmoid tumors at the European Society of Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress, being held in Barcelona from 13-17 September 2024 (Press release, Immunome, SEP 13, 2024, View Source [SID1234646599]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Enrollment in the Phase 3 portion of RINGSIDE was completed in February 2024, and Immunome expects to report topline data from that trial in the second half of 2025.

Following the presentation, a copy of the poster will be made available in the "Events & Presentations" portion of Immunome’s website.

Poster Presentation Details:

Title: Updated Results of the RINGSIDE Phase 2 Trial and Open-Label Extension of AL102 for the Treatment of Desmoid Tumors (Abstract #1766P)

Presenter: Bernd Kasper, MD, PhD, Mannheim Cancer Center at the Mannheim University Medical Center,

Date: September 14, 2024